{"groups":[{"description":"Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.","id":"FG000","title":"Thalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: clerical error"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Ineligible: wrong cell type"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible: inadequate pathology"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Never Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"55"}],"type":"STARTED"},{"achievements":[{"comment":"Eligible and treated patients.","groupId":"FG000","numSubjects":"45"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 9/4/2001 and closed to accrual on 3/3/2008 (suspended from 6/30/2003 to 8/1/2005)."}